semaglutide approved for cardiovascular Weight loss drug reduces risk of adverse events by 20% among overweight, obese patients FDA Approves Semaglutide for New
Description
doi: 10.1016/j.jchromb.2023.123688
The Role of GLP-1 Agonists in Esthetic Medicine: Exploring the Impact of Semaglutide on Body Contouring and Skin Health
The hazard ratio for the first year of follow-up was used to assess potential bias because an increased risk that is restricted to this period might not be biologically plausible
S.DonahooW
These are small, repeatable steps
